Literature DB >> 6123988

Comparison of VIP-secretin receptors in rat and human lung.

J Christophe, P Chatelain, G Taton, M Delhaye, M Waelbroeck, P Robberecht.   

Abstract

The binding of 125I-VIP (Vasoactive Intestinal Peptide) to a crude particulate fraction from a rat lung was reversible and 125-I-VIP dissociation was accelerated by guanine triphosphate nucleotides. The relative potency of VIP and related peptides to compete with 125-VIP for binding was similar to their ability to stimulate adenylate cyclase in the same preparation. Dose-effect curves were compatible with the existence of two classes of VIP-receptors: a high-affinity type with equal affinity for VIP and [Val5] secretin, and a low-affinity type with affinity decreasing in the order VIP greater than [Val5] secretin greater than secretin. The response of a crude particulate adenylate cyclase preparation from human lung was also investigated. The biphasic pattern of adenylate cyclase stimulation by VIP suggested the presence of high- and low-affinity VIP receptors coupled to the enzyme. In addition, the stimulation of adenylate cyclase by secretin and [Val5] secretin was also biphasic, suggesting the coexistence of high- and low-affinity secretin receptors, Secretin (7-27) inhibited completely the secretin-stimulated activity operating through high-affinity secretion receptors, so that these receptors appear to be genuine secretin-preferring receptors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6123988     DOI: 10.1016/0196-9781(81)90040-1

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

1.  Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

Authors:  M Xia; S P Sreedharan; E J Goetzl
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

2.  Effects of secretin on content of PGE2 and 6-keto PGF1 alpha in gastric mucosa.

Authors:  T Mine; J Fujisaki; K Akimoto; S Yoshida; Y Hasegawa; E Ogata
Journal:  Dig Dis Sci       Date:  1988-12       Impact factor: 3.199

3.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

4.  Insight into Evolution and Conservation Patterns of B1-Subfamily Members of GPCR.

Authors:  Chiranjib Chakraborty; Sang-Soo Lee; Ashish Ranjan Sharma; Garima Sharma; Manojit Bhattacharya
Journal:  Int J Pept Res Ther       Date:  2020-02-08       Impact factor: 1.931

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.